A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00410540|
Recruitment Status : Completed
First Posted : December 13, 2006
Last Update Posted : April 27, 2010
|Condition or disease||Intervention/treatment||Phase|
|Pain Analgesics, Opioid||Drug: OROS hydromorphone HCL ; Morphine sulfate||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||202 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-Blind, Controlled Trial of Hydromorphone (Immediate and Sustained- Release) vs Morphine (Immediate and Sustained-release) in Cancer Pain|
|Actual Study Completion Date :||May 2001|
- The primary efficacy : Patient's assessment of "worst pain in the past 24 hours" Brief Pain Inventory (BPI) questions, scored daily in the patient's diary.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00410540
|Study Director:||Alza Corporation Clinical Trial||ALZA|